⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KLRS News
Kalaris Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
KLRS
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
KLRS
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
globenewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
globenewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
globenewswire.com
KLRS
Form 8-K
sec.gov
KLRS
Kalaris Appoints Laurie Keating to Board of Directors
globenewswire.com
KLRS
PEPG
IMRX
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
globenewswire.com
KLRS